Cuize Medicine Overview
- Year Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.59M
- Investors
-
3
Cuize Medicine General Information
Description
Developer of pulmonary therapy medication intended to be used for the perioperative period. The company developed a sustained release technology platform and inhalation powder technology platform, enabling to reduce side effects and delivers sustained curative effects without burst release phenomenon to pulmonary patients.
Contact Information
Corporate Office
- Room 3A03, Building 2, No. 339
- No. 25 Road, Baiyang Street, Hangzhou Economic and Technological Development Zone
- Hangzhou, Zhejiang 310000
- China
Corporate Office
- Room 3A03, Building 2, No. 339
- No. 25 Road, Baiyang Street, Hangzhou Economic and Technological Development Zone
- Hangzhou, Zhejiang 310000
- China
Cuize Medicine Timeline
Cuize Medicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 26-Jun-2025 | $4.59M | Completed | Generating Revenue | ||
| 4. Later Stage VC | 29-Sep-2024 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 11-May-2023 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Open Market | 25-Aug-2022 | $443K | Completed | Generating Revenue | ||
| 1. Joint Venture | 08-Jul-2019 | Completed | Generating Revenue |
Cuize Medicine Patents
Cuize Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260232646-A1 | Method for treating postoperative pain and use thereof | Pending | 11-Feb-2025 | ||
| WO-2026171186-A1 | Method for treating postoperative pain and use thereof | Pending | 11-Feb-2025 | ||
| WO-2026171186-A9 | Method for treating postoperative pain and use thereof | Pending | 11-Feb-2025 | ||
| WO-2026171187-A1 | Stable crystal of ropivacaine | Pending | 11-Feb-2025 | ||
| US-20260234109-A1 | Stable ropivacaine crystals | Pending | 11-Feb-2025 | C07D211/60 |
Cuize Medicine Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jiangguo Investment Management | Venture Capital | Minority | ||
| Goldport Capital | Venture Capital | Minority | ||
| Zhejiang Xianju Pharmaceutical Company | Corporation | Majority |
Cuize Medicine FAQs
-
When was Cuize Medicine founded?
Cuize Medicine was founded in 2019.
-
Where is Cuize Medicine headquartered?
Cuize Medicine is headquartered in Hangzhou, China.
-
What industry is Cuize Medicine in?
Cuize Medicine’s primary industry is Drug Discovery.
-
Is Cuize Medicine a private or public company?
Cuize Medicine is a Private company.
-
What is the current valuation of Cuize Medicine?
The current valuation of Cuize Medicine is .
-
What is Cuize Medicine’s current revenue?
The current revenue for Cuize Medicine is .
-
How much funding has Cuize Medicine raised over time?
Cuize Medicine has raised $12.6M.
-
Who are Cuize Medicine’s investors?
Jiangguo Investment Management, Goldport Capital, and Zhejiang Xianju Pharmaceutical Company have invested in Cuize Medicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process